Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds

Kenneth J. Smith; Bruce Y. Lee; Mary Patricia Nowalk; Mahlon Raymund; Richard K. Zimmerman

doi:10.1016/j.vaccine.2010.09.053

Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds

Kenneth J. Smith, Bruce Y. Lee, Mary Patricia Nowalk, Mahlon Raymund, Richard K. Zimmerman

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Influenza vaccination is now recommended for all ages; CDC pneumococcal polysaccharide vaccination (PPV) recommendations are comorbidity-based in nonelderly patients. We constructed a Markov model to estimate the cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Patients were followed for 10 years, with differing time horizons examined in sensitivity analyses. With 100% vaccine uptake, dual vaccination cost $37,700/QALY gained compared to a CDC recommendation strategy; with observed vaccine uptake, dual vaccination cost $5,300/QALY. Results were sensitive to shorter time horizons, favoring CDC recommendations. We found dual vaccination of all 50-year-olds economically reasonable. Shorter duration models may not fully account for PPV effectiveness.

Original language	English (US)
Pages (from-to)	7620-7625
Number of pages	6
Journal	Vaccine
Volume	28
Issue number	48
DOIs	https://doi.org/10.1016/j.vaccine.2010.09.053
State	Published - Nov 10 2010
Externally published	Yes

Keywords

Cost-effectiveness
Influenza vaccine
Pneumococcal polysaccharide vaccine
Secondary pneumococcal pneumonia

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2010.09.053

Cite this

@article{14605679c4cb4c26b8efc9f660131c71,

title = "Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds",

abstract = "Influenza vaccination is now recommended for all ages; CDC pneumococcal polysaccharide vaccination (PPV) recommendations are comorbidity-based in nonelderly patients. We constructed a Markov model to estimate the cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Patients were followed for 10 years, with differing time horizons examined in sensitivity analyses. With 100% vaccine uptake, dual vaccination cost $37,700/QALY gained compared to a CDC recommendation strategy; with observed vaccine uptake, dual vaccination cost $5,300/QALY. Results were sensitive to shorter time horizons, favoring CDC recommendations. We found dual vaccination of all 50-year-olds economically reasonable. Shorter duration models may not fully account for PPV effectiveness.",

keywords = "Cost-effectiveness, Influenza vaccine, Pneumococcal polysaccharide vaccine, Secondary pneumococcal pneumonia",

author = "Smith, {Kenneth J.} and Lee, {Bruce Y.} and Nowalk, {Mary Patricia} and Mahlon Raymund and Zimmerman, {Richard K.}",

year = "2010",

month = nov,

day = "10",

doi = "10.1016/j.vaccine.2010.09.053",

language = "English (US)",

volume = "28",

pages = "7620--7625",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "48",

}

TY - JOUR

T1 - Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds

AU - Smith, Kenneth J.

AU - Lee, Bruce Y.

AU - Nowalk, Mary Patricia

AU - Raymund, Mahlon

AU - Zimmerman, Richard K.

PY - 2010/11/10

Y1 - 2010/11/10

N2 - Influenza vaccination is now recommended for all ages; CDC pneumococcal polysaccharide vaccination (PPV) recommendations are comorbidity-based in nonelderly patients. We constructed a Markov model to estimate the cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Patients were followed for 10 years, with differing time horizons examined in sensitivity analyses. With 100% vaccine uptake, dual vaccination cost $37,700/QALY gained compared to a CDC recommendation strategy; with observed vaccine uptake, dual vaccination cost $5,300/QALY. Results were sensitive to shorter time horizons, favoring CDC recommendations. We found dual vaccination of all 50-year-olds economically reasonable. Shorter duration models may not fully account for PPV effectiveness.

AB - Influenza vaccination is now recommended for all ages; CDC pneumococcal polysaccharide vaccination (PPV) recommendations are comorbidity-based in nonelderly patients. We constructed a Markov model to estimate the cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Patients were followed for 10 years, with differing time horizons examined in sensitivity analyses. With 100% vaccine uptake, dual vaccination cost $37,700/QALY gained compared to a CDC recommendation strategy; with observed vaccine uptake, dual vaccination cost $5,300/QALY. Results were sensitive to shorter time horizons, favoring CDC recommendations. We found dual vaccination of all 50-year-olds economically reasonable. Shorter duration models may not fully account for PPV effectiveness.

KW - Cost-effectiveness

KW - Influenza vaccine

KW - Pneumococcal polysaccharide vaccine

KW - Secondary pneumococcal pneumonia

UR - http://www.scopus.com/inward/record.url?scp=78249269475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78249269475&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.09.053

DO - 10.1016/j.vaccine.2010.09.053

M3 - Article

C2 - 20887828

AN - SCOPUS:78249269475

SN - 0264-410X

VL - 28

SP - 7620

EP - 7625

JO - Vaccine

JF - Vaccine

IS - 48

ER -

Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this